Watchdog Group Blasts FDA’s Dwindling Oversight Of Non-Clinical Labs
This article was originally published in The Gray Sheet
Executive SummaryA nonprofit government watchdog group is criticizing FDA for scaling back inspections of laboratories that test medical devices early in the development process, before they are tested in humans
You may also be interested in...
Device industry experts say a seemingly minor footnote to the recent 510(k) program draft guidance could create a new requirement for nonclinical studies.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.